Home
Overview
Membership
Advisory board
Institutional Review Board (IRB)
MCOG | Aswan 2023
Clinical studies
Practice guidelines
Community campaigns
Artificial intelliegence (AI) unit
MOGGEsoft
SilverAxon Inc.
MOGGE books
Research fellowship
Board of directors (BOD)
Team
Plans & Pricing
More
Primary outcome of the study will be cancer-specific survival (CSS) rate at 3 and 5
years after initiation of treatment. Recurrence-free survival (RFS) rate at 3 and 5 years constitutes the secondary outcome
4/11-5/12